{'fraction_non_alphanumeric': 0.023064250411861616, 'fraction_numerical': 0.02800658978583196, 'mean_word_length': 5.01980198019802, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Clinical studies of PC 904 in pediatrics (author's transl)].

PC-904 was administered to 3 pediatric patients with serious infections resistant clinically to other antibiotics (2 cases of sepsis and 1 case of pseudomonal pneumonia). Daily dosage was 100 approximately 150 mg/kg and intravenous infusions were carried out in 2 or 3 divided doses. This drug showed clinically and bacteriologically good response in these patients without any side effect, and was considered to be a useful drug or worthwhile to use in the treatment of the serious infectious diseases such as sepsis or pseudomonal infections.